NIH-led researchers develop software that could facilitate drug development
AptaTRACE is the first algorithm that uses the full scope of sequencing data from a large number of selection rounds to capture sequence and structure features of aptamers that bind to the target.
A team of researchers led by a National Institutes of Health investigator, Teresa Przytycka, has developed a new software tool called AptaTRACE that could be an important advance for drug developers and other scientists who want to identify molecules that bind with high precision to targets of interest.
“This research is an excellent example of how the benefits of ‘big data’ critically depend upon the existence of algorithms that are capable of transforming such data into information,” said Dr Przytycka, a senior investigator at the National Center for Biotechnology Information (NCBI), a division of the NIH’s National Library of Medicine.
Aptamers are short RNA or DNA molecules that are capable of binding with high affinity and specificity to diverse biological targets. Aptamers bind to their targets because of features of their sequence and structure that are complementary to the biochemical characteristics of the target’s surface. Possible targets of aptamers include small organic molecules, proteins or protein complexes, virus surfaces and entire cells. This broad range of targets makes aptamers candidates for a wide variety of applications, ranging from molecular biosensors to drug delivery systems to antibody replacement.
AptaTRACE is designed for use in conjunction with High-Throughput Systematic Evolution of Ligands by Exponential Enrichment (HT-SELEX), a laboratory technique for identifying aptamers. HT-SELEX allows analyses of millions of sequences to identify the candidates that undergo selection for binding to the target.
The AptaTRACE tool analyses this data to find the common features (or “motifs”) among the sequences that bind.
AptaTRACE is the first algorithm that uses the full scope of sequencing data from a large number of selection rounds to capture sequence and structure features of aptamers that bind to the target. Such information allows researchers to better understand why some molecules bind and others do not. Understanding these binding motifs is critical for taking advantage of the aptamers identified via the HT-SELEX process to enable modifications that transform aptamers into drug delivery systems targeting specific cells, for example. Research describing AptaTRACE is published in the July 27 issue of Cell Systems.
AptaTRACE is the result of a collaboration between Dr Przytycka’s group and researchers from the Beckman Research Institute of City of Hope, Duarte, California, led by Dr. John Burnett, and from Freiburg University, Breisgau, Germany, led by Dr Rolf Backofen. The tool can be downloaded from NCBI at www.ncbi.nlm.nih.gov/CBBresearch/Przytycka/index.cgi#aptatools, as well as Cell Systems.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance